Know what is Blood Dyscrasia, It’s Symptoms, Causes and Treatment
Blood dyscrasia is generally described as a health condition where patients tend to experience an imbalance in the blood components. A person suffering from blood dyscrasia might have a smaller number of RBCs (Red More...
Guatemala: Locally acquired Zika virus infection confirmed
Following earlier reports on Outbreak News Today of local transmission of Zika virus in El Salvador, Mexico and Paraguay, the World Health Organization reports receiving notification of a laboratory-confirmed autochthonous More...
CLL drug, Imbruvica, receives FDA approval for expanded use
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which More...
Gilead Sciences cancer drug, Zydelig, receives FDA approval
The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic More...
Pharmacyclics CLL drug, Imbruvica gets FDA approval
PRESS RELEASE The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy. CLL is More...
Gazyva for chronic lymphocytic leukemia receives FDA approval
The U.S. Food and Drug Administration today approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL). CLL is a blood More...
FDA updates ‘box warning’ for Arzerra and Rituxan to include Hepatitis B reactivation risk
The US Food and Drug Administration (FDA) announced Wednesday the approval of changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to More...
